Timeline
Oxford Nanopore Technologies
Broker sees scope for upgrades after Oxford Nanopore's earnings beat
Oxford Nanopore narrows loss, says its tracking toward breakeven in 2027
Broker sees downside risk ahead of Oxford Nanopore first results under new CEO
Oxford Nanopore appoints first CMO and new CIO
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.